Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027

Fig. 1

Kaplan–Meier survival analysis in the full analysis set (n = 37). a Progression-free survival (PFS)a. b Overall survival (OS). c Time to treatment failure (TTF). Abbreviations: CI confidence interval, NR not reached, QOD every other day. aPFS was censored for four patients receiving afatinib < 20 mg/day. These patients were treated as censored when they fell below the 20 mg/day minimum dose specified in the protocol

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us